^
Association details:
Biomarker:MAP2K1 P124Q
Cancer:Melanoma
Drug:VTX-11e (ERK2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Excerpt:
...examined two BRAF-mutant melanoma cell lines with endogenous MEK1P124Q (SMU030P) and MEK1P124L (D28; ref. 34) mutations... when compared with a small panel of BRAFV600/MEK1 wild-type melanoma cell lines, the SMU030P and D28 cell lines showed intermediate sensitivity to dabrafenib, but were exquisitely sensitive to the downstream MEK and ERK inhibitors, trametinib and VX-11e...
DOI:
10.1158/1078-0432.CCR-14-0759